1McDougall A;McNally PG;Fitch M.Insulin treated patients with type 2 diabetes mellitus have higher rates of nocturnal than day time hypoglycaemia:continuous blood glucose monitoring run-in data from the Reach study,2004(z1).
6Weyer C, Bogardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest, 1999,104:787-794.
7Roder ME, Porte D Jr, Schwartz RS, et al. Disproportionately elevated proinsulin levels reflect the degree of impaired B-cell secretory capacity in patients with non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab, 1998,83:604-608.
8Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care, 2004,27:1265-1270.
9Toschi E, Camastra S, Sironi AM, et al. Effect of acute hyperglycemia on insulin secretion in humans. Diabetes, 2002,51:S130-S133.
10Kalbag JB, Walter YH, Nedelman JR, et al. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. Diabetes Care, 2001,24:73-77.
